
Pfizer PFE
Quarterly report 2025-Q3
added 11-04-2025
Country |
|
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NYSESPB |
Shares |
5.66 B |
Market Cap[1] |
$ 141 B |
EBITDA (LTM) |
$ 6.66 B |
P/E (LTM) |
10.2 |
P/S (LTM) |
2.25 |
EPS (LTM) |
2.44 |
Pfizer is a global pharmaceutical company that has been in operation for over 170 years. The company is headquartered in New York City and has a presence in over 150 countries worldwide. Pfizer's mission is to discover, develop, and deliver innovative medicines and vaccines that improve the lives of people around the world.
Pfizer has a diverse portfolio of products that address a range of health conditions, including cardiovascular disease, oncology, inflammation, immunology, and rare diseases. Some of the company's most well-known products include Lipitor, Viagra, and Lyrica.
In addition to developing new treatments, Pfizer is committed to improving access to healthcare for people in need. The company has established partnerships with governments, non-governmental organizations, and healthcare providers to expand access to its medicines and vaccines.
Pfizer is also dedicated to sustainability and reducing its environmental impact. The company has set ambitious goals to reduce greenhouse gas emissions, water consumption, and waste generation across its operations.
As a leading pharmaceutical company, Pfizer is constantly innovating and adapting to meet the changing needs of patients and healthcare providers. With a focus on research and development, access to healthcare, and sustainability, Pfizer is poised to continue making a positive impact on global health for years to come.
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market | ||
|
Aclaris Therapeutics
ACRS
|
$ 3.01 | 3.79 % | $ 233 M | Nasdaq Global Select Market | ||
|
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | ||
|
Alterity Therapeutics Limited
ATHE
|
$ 3.1 | 1.31 % | $ 7.46 B | Nasdaq Capital Market | ||
|
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | ||
|
Ampio Pharmaceuticals
AMPE
|
- | -11.43 % | $ 502 K | NYSE American | ||
|
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | ||
|
Alpine Immune Sciences
ALPN
|
- | - | $ 2.17 B | Nasdaq Global Market | ||
|
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | ||
|
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | ||
|
Avenue Therapeutics
ATXI
|
- | -52.27 % | $ 4.45 M | Nasdaq Global Select Market | ||
|
Aptorum Group Limited
APM
|
$ 1.09 | -2.25 % | $ 5.94 M | Nasdaq Global Select Market | ||
|
Autolus Therapeutics plc
AUTL
|
$ 1.95 | -1.27 % | $ 498 M | Nasdaq Global Select Market | ||
|
AVROBIO
AVRO
|
- | 1083.1 % | $ 745 M | Nasdaq Global Select Market | ||
|
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | ||
|
Ascendis Pharma A/S
ASND
|
$ 212.41 | 1.48 % | $ 5 B | Nasdaq Global Select Market | ||
|
BioDelivery Sciences International
BDSI
|
- | -4.8 % | $ 255 M | Nasdaq Global Select Market | ||
|
Athersys
ATHX
|
- | 3.77 % | $ 22.4 M | Nasdaq Capital Market | ||
|
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX | ||
|
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | ||
|
BioVie
BIVI
|
$ 1.14 | 0.49 % | $ 1.68 M | Nasdaq Capital Market | ||
|
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market | ||
|
Bellicum Pharmaceuticals
BLCM
|
- | -9.72 % | $ 5.89 M | Nasdaq Capital Market | ||
|
Berkeley Lights
BLI
|
- | -7.31 % | $ 87 M | Nasdaq Global Select Market | ||
|
Adaptimmune Therapeutics plc
ADAP
|
- | -15.15 % | $ 60.3 M | Nasdaq Global Select Market | ||
|
Can-Fite BioPharma Ltd.
CANF
|
$ 0.2 | 6.23 % | $ 435 M | NYSE American | ||
|
bluebird bio
BLUE
|
- | - | $ 546 M | Nasdaq Global Select Market,SPB | ||
|
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | ||
|
BioNTech SE
BNTX
|
$ 94.97 | -0.33 % | $ 27.2 B | Nasdaq Global Select Market | ||
|
Amphastar Pharmaceuticals
AMPH
|
$ 26.71 | -1.07 % | $ 1.29 B | Nasdaq Global Select Market | ||
|
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market | ||
|
Anika Therapeutics
ANIK
|
$ 9.6 | 0.52 % | $ 141 M | Nasdaq Global Select Market,SPB | ||
|
Calithera Biosciences
CALA
|
- | -10.95 % | $ 876 K | Nasdaq Global Select Market | ||
|
Arena Pharmaceuticals
ARNA
|
- | -6.81 % | $ 3.04 B | Nasdaq Global Select Market,SPB | ||
|
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | ||
|
Axon Enterprise
AXON
|
$ 570.58 | -0.27 % | $ 43.2 B | Nasdaq Global Select Market,SPB | ||
|
Catalyst Biosciences
CBIO
|
$ 11.67 | 0.56 % | $ 768 M | Nasdaq Capital Market | ||
|
Ayala Pharmaceuticals
AYLA
|
- | - | $ 7.46 M | Nasdaq Global Market | ||
|
Aytu BioScience
AYTU
|
$ 2.58 | 1.18 % | $ 16.2 M | Nasdaq Capital Market | ||
|
AstraZeneca PLC
AZN
|
$ 92.13 | -0.41 % | $ 96.9 B | Nasdaq Global Select Market | ||
|
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | ||
|
Brickell Biotech
BBI
|
- | -5.38 % | $ 6.06 M | Nasdaq Capital Market | ||
|
Burford Capital Limited
BUR
|
$ 8.88 | -1.5 % | $ 1.46 B | NYSE | ||
|
ChromaDex Corporation
CDXC
|
- | -0.88 % | $ 598 M | Nasdaq Capital Market | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$ 11.36 | -2.41 % | $ 735 M | NYSE | ||
|
Biogen
BIIB
|
$ 176.12 | -0.16 % | $ 25.6 B | Nasdaq Global Select Market,SPB | ||
|
Certara
CERT
|
$ 8.78 | -0.9 % | $ 1.41 B | Nasdaq Global Select Market | ||
|
Cerevel Therapeutics Holdings
CERE
|
- | - | $ 7.29 B | Nasdaq Capital Market |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.